The FcRn class arrived in GCC in 2023 — but formulary criteria haven't caught up, so pyridostigmine and steroids still anchor 85%+ of treated patients.
Pyridostigmine plus corticosteroids or azathioprine remains the dominant regimen for an estimated 85% or more of GCC myasthenia gravis patients, a generic backbone that is MOH formulary-listed and universally available. Diagnosis itself is the first bottleneck: AChR-antibody testing is available at roughly 20 centres across the six GCC states, concentrated in Riyadh, Dubai, Abu Dhabi, and Doha, and presentation is frequently delayed by clinicians attributing ptosis or diplopia to the region's high rates of thyroid disease rather than to myasthenia gravis. Anti-MuSK antibody testing is available at even fewer sites, leaving a share of seronegative and MuSK-positive patients under-characterised.
Efgartigimod (Vyvgart), argenx's FcRn antagonist, registered with SFDA and UAE MOH in 2023 and is now available at KFSH&RC, AUH, and Hamad Medical Corporation via argenx's GCC distribution partnership with Takeda — the first novel MG mechanism to reach the region. Uptake stands at an estimated 200-300 patients as of mid-2024, almost entirely refractory generalised MG failing pyridostigmine, steroids, and azathioprine. Eculizumab (Soliris) is technically registered for refractory AChR-positive gMG via its existing PNH approval but sees very low utilisation: NPHC has not established MG-specific coverage criteria, and the C5 inhibitor's price sits without a defined reimbursement pathway for this indication. NPHC formulary inclusion for efgartigimod, not yet in place, is the access trigger that would move the region from named-patient prescription to standard reimbursed care.
Approved myasthenia gravis agents — GCC, 2024
| Drug (Brand / INN) | Mechanism | Company | GCC Registration | Key Trial Result | GCC Access Status |
|---|---|---|---|---|---|
| Vyvgart (efgartigimod alfa) | FcRn antagonist IV/SC | argenx | SFDA 2023; MOH UAE 2023 | 68% MG-ADL responder vs placebo (ADAPT) | Registered; specialist neurology access at KFSH&RC, AUH, HMC; not yet formulary-listed at most government pharmacies |
| Soliris (eculizumab) for MG | C5 complement inhibitor IV | AstraZeneca / Alexion | SFDA registered (PNH approval extended to MG) | QMG −4.2 vs −1.1 placebo (REGAIN) | Technically available; very low utilisation — NPHC MG-specific coverage criteria not established |
| Mestinon + steroids/AZA | AChE inhibitor + immunosuppression | Generic | Generic; dominant across GCC | Standard-of-care evidence base | Dominant SoC in 85%+ of patients; MOH formulary listed; widely available |
Sources: SFDA registration records; MOH UAE rare disease formulary documentation; NEJM ADAPT (efgartigimod); REGAIN trial (eculizumab in gMG); Al-Shubaili AF et al. Eur Neurol 2012; GCC neurology network database; argenx GCC market access reports 2024; KFSH&RC neurology service data.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Current NPHC/MOH coverage posture for efgartigimod
- specialist-prescription and insurance pre-authorisation pathways
- the formulary-listing triggers argenx is pursuing
Delivers
- Prescribing posture at KFSH&RC, AUH, and Hamad Medical Corporation
- the ~20-centre AChR testing network
- thymoma-screening gaps affecting up to 10-15% of MG patients
Delivers
- NPHC coverage-criteria gap for C5 inhibition in MG
- AChR+ eligibility restriction
- positioning lessons for FcRn vs complement mechanisms entering the Gulf
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Why AChR-antibody testing exists at only about 20 centres across the six GCC states, concentrated in Riyadh, Dubai, Abu Dhabi, and Doha.
- How the region's high rates of thyroid disease delay MG diagnosis, since clinicians often attribute ptosis or diplopia to thyroid causes first.
- Vyvgart (efgartigimod), argenx's FcRn antagonist registered with SFDA and MOH UAE in 2023, delivered a 68% MG-ADL responder rate versus placebo in the ADAPT trial.
- Soliris (eculizumab) versus generic pyridostigmine plus steroids or azathioprine, the dominant regimen for an estimated 85% or more of GCC MG patients.
- Why anti-MuSK antibody testing is available at even fewer sites than AChR testing, leaving seronegative and MuSK-positive patients under-characterised.
- How thymoma-screening gaps affect an estimated 10 to 15% of MG patients, per GCC thoracic surgery network reporting.
- Why NPHC formulary inclusion for efgartigimod, not yet in place, is the trigger that would shift the region from named-patient prescription to standard reimbursed care.
- How eculizumab's MG registration has outpaced its access, since NPHC has not established MG-specific coverage criteria or a defined reimbursement pathway.
- How efgartigimod's SFDA and MOH UAE registrations, both dated 2023, moved through argenx's GCC distribution partnership with Takeda.
- Why specialist access today concentrates at three centres, KFSH&RC, AUH, and Hamad Medical Corporation, rather than broad government-pharmacy listing.
- Why efgartigimod's estimated 200 to 300 GCC patients as of mid-2024 are almost entirely refractory generalised MG cases failing pyridostigmine, steroids, and azathioprine.
- Which GCC neurology centres, KFSH&RC, AUH, and Hamad Medical Corporation, anchor current prescribing posture for the novel FcRn mechanism.
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA, SFDA, MOH, ClinicalTrials.gov), peer-reviewed literature, and live payer/formulary policy documentation — not secondary summaries. Findings are independently verified before inclusion.
Myasthenia Gravis GCC CI sources: SFDA drug registration records, MOH UAE rare disease formulary documentation, ADAPT trial (efgartigimod, NEJM), REGAIN trial (eculizumab in gMG), Al-Shubaili AF et al. Eur Neurol 2012, GCC neurology network database, argenx GCC market access reports 2024, KFSH&RC neurology service data, and GCC thoracic surgery network 2022 reporting on thymoma-screening gaps.
- Drug registration status verified against SFDA and MOH UAE formulary documentation
- Clinical trial results verified against published primary sources (NEJM ADAPT, REGAIN)
- GCC prescribing and access patterns verified against argenx market access reporting and KFSH&RC neurology service data
- Diagnostic infrastructure figures verified against GCC neurology network database and published epidemiology (Al-Shubaili AF et al.)
Frequently asked questions
Commission this brief
AXLRx delivers Myasthenia Gravis competitive intelligence for the GCC market, built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.